Almac Diagnostic Collaborates with Queen’s University to Bring Personalized Chemotherapy for Esophageal Cancer

 Almac Diagnostic Collaborates with Queen’s University to Bring Personalized Chemotherapy for Esophageal Cancer

Almac Diagnostic Collaborates with Queen’s University to Bring Personalized Chemotherapy for Esophageal Cancer

Shots:

  • Almac Diagnostic and Queen’s University validate a test to decide the chemotherapy to be used for early-stage esophageal cancer to remove the tumor, improve prognosis and QoL
  • The focus of the collaboration is to bring personalized therapies for esophageal cancer. Additionally, Almac Diagnostic has developed DNA Damage Immune Response (DDIR) Signature to personalize chemotherapy for breast cancer
  • The test increases the molecular understanding of each patient’s cancer and enables the clinicians to decide the right chemotherapy to shrink the tumor

Click here to read full press release/ article | Ref: Almac Diagnostic | Image: Glassdoor

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post